On September 3, CSPC PHARMA rose 3.11% in regular trading, trading at HK$9.535/share, with turnover of HK$209 million. The rally was driven by a cluster of R&D pipeline catalysts released in recent days.
On September 1, the company's core candidate SYS6010 received Breakthrough Therapy Designation from China's NMPA for the treatment of recurrent or metastatic head and neck squamous cell carcinoma. The same day, a Phase I clinical trial of SYH2056 tablets for depression was officially initiated in China. On August 31, the company launched a Phase I trial of its self-developed amylin receptor agonist SYH2092 injection for weight management at the first study center in China, a product seen as a high-potential candidate in the obesity and type 2 diabetes space.
These milestones follow a series of earlier positive developments, including SYS6010 meeting its primary progression-free survival endpoint in a Phase III non-small cell lung cancer trial, and SYS6090 receiving FDA Fast Track designation for metastatic colorectal cancer. Multiple investment banks, including Goldman Sachs, Citi, and Morgan Stanley, recently raised their target prices, with the consensus average at approximately HK$12.33.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments